Press Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 27, 2014Patient Recruitment Now Underway at Treatment Centers Across the United States
Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate...
-
Feb 24, 2014Patient Recruitment and Enrollment Now Underway
Eisai Inc. today announced that patient recruitment and enrollment are currently underway for CAMELLIA-TIMI 61, a randomized double-blind,...
-
Feb 12, 2014
Eisai Inc. announced today that its subsidiary Eisai Laboratorios Ltda has filed for the marketing authorization of BELVIQ as a treatment for...
-
Feb 10, 2014Number of Insured Commercial Lives in the U.S. with Coverage for BELVIQ® Now Exceeds 50 Percent
Eisai Inc. reported today that it has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit...
-
Feb 2, 2014
Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint. Compared to...